Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 7/20 | 0.40 |
| ▸ | MTNR1B | P49286 | 7/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | NQO2 | P16083 | 5/20 | 0.38 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 2/20 | 0.38 |
| ▸ | CA2 | P00918 | 2/20 | 0.38 |
| ▸ | ACHE | P22303 | 2/20 | 0.38 |
| ▸ | DRD2 | P14416 | 5/20 | 0.37 |
| ▸ | DRD3 | P35462 | 5/20 | 0.37 |
| ▸ | DRD4 | P21917 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL990622 | 0.92 | POLA1 (0.41) | MTNR1AMTNR1BKMT2ANQO2OPRM1 | |
| SCHEMBL10998258 | 0.76 | KDM1A (0.46) | KMT2AOPRM1 | |
| SCHEMBL19995876 | 0.73 | KMT2A (0.41) | KMT2AOPRM1 | |
| SCHEMBL5859227 | 0.71 | CYP19A1 (0.53) | MTNR1AMTNR1BKMT2ACA1CA2 | |
| SCHEMBL2305878 | 0.71 | CYP26A1 (0.56) | MTNR1AMTNR1BKMT2ACA1CA2 | |
| SCHEMBL4911889 | 0.70 | OPRM1 (0.42) | OPRM1 | |
| SCHEMBL1470331 | 0.69 | MTNR1A (0.60) | MTNR1AMTNR1BNQO2 | |
| SCHEMBL821099 | 0.69 | PPARD (0.60) | MTNR1AMTNR1BNQO2 | |
| SCHEMBL12035617 | 0.69 | PPARD (0.60) | MTNR1AMTNR1BNQO2 | |
| SCHEMBL821443 | 0.69 | PPARD (0.60) | MTNR1AMTNR1BNQO2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7691861-B2 | Indolymaleimide derivatives | NOVARTIS AG (CH) | 2010-04-06 | — | — | US | disclosed |
| US-20080234494-A1 | Indolylmaleimide Derivatives | NOVARTIS AG (CH) | 2008-09-25 | — | — | US | disclosed |
| EP-1709030-B1 | INDOLYLMALEIMIDE DERIVATIVES | NOVARTIS AG (CH) | 2008-04-02 | — | — | EP | disclosed |
| EP-1709030-A1 | INDOLYLMALEIMIDE DERIVATIVES | Novartis AG (CH) | 2006-10-11 | — | — | EP | disclosed |
| WO-2005068454-A1 | INDOLYLMALEIMIDE DERIVATIVES | NOVARTIS AG (CH) | 2005-07-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080234494-A1 | Indolylmaleimide Derivatives | IDH3A, INMT, IDH2 | MTNR1A 79/4885MTNR1B 65/4885KMT2A 1853/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.